{"id":548691,"date":"2025-06-18T10:00:00","date_gmt":"2025-06-18T14:00:00","guid":{"rendered":"https:\/\/www.mdbriefcase.com\/postcall-item\/%f0%9f%a9%ba-did-450-crack-the-ozempic-market\/"},"modified":"2025-06-18T10:00:00","modified_gmt":"2025-06-18T14:00:00","slug":"%f0%9f%a9%ba-did-450-crack-the-ozempic-market","status":"publish","type":"postcall","link":"https:\/\/www.mdbriefcase.com\/fr\/postcall-item\/%f0%9f%a9%ba-did-450-crack-the-ozempic-market\/","title":{"rendered":"\ud83e\ude7a Did $450 crack the Ozempic market?"},"content":{"rendered":"

<\/p>\n

\n
\n
\n
\n

\ud83e\ude7a Did $450 crack the Ozempic market?<\/h1>\n

PLUS: Kidney fallout, AI accuracy, & gene therapy<\/h2>\n
\n
\n
\n
\n
<\/div>\n
\n

June 18, 2025 <\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n
<\/circle><\/path><\/svg><\/div>\n

<\/a><\/p>\n

<\/circle><\/path><\/svg><\/div>\n

<\/a><\/p>\n

<\/circle><\/path><\/svg><\/div>\n

<\/a><\/p>\n

<\/circle><\/path><\/svg><\/div>\n

<\/a><\/div>\n<\/div>\n<\/div>\n

\n
\n
\"\"<\/div>\n<\/div>\n
\n

Good morning!<\/b><\/p>\n<\/div>\n

\n

One of the world\u2019s richest drugmakers <\/span>didn\u2019t pay a $450 bill<\/a><\/span> \u2014 and may have opened the floodgates for generic Ozempic in Canada. <\/span>While the US market is locked until 2032, Novo Nordisk let its semaglutide patent lapse north of the border. (No, it can\u2019t be revived.)<\/span>\u00a0<\/span>A $450 mistake. Multibillion-dollar consequences. Bureaucracy giveth, bureaucracy taketh away.<\/span><\/p>\n<\/div>\n

\n

Today\u2019s issue takes 5 minutes to read<\/span>. Only got one? Here\u2019s what to know: <\/p>\n<\/div>\n

\n